Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2015

Open Access 01-12-2015 | Study protocol

Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy

Authors: Claire M. White, Robert D. Hadden, Sarah F. Robert-Lewis, Paul R. McCrone, Jane L. Petty

Published in: BMC Neurology | Issue 1/2015

Login to get access

Abstract

Background

Inflammatory neuropathies such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and paraproteinaemic demyelinating neuropathy are a heterogenous group of peripheral nerve disorders that affect around one to two people per 100,000. Whilst treatments such as intravenous immunoglobulin, plasma exchange and corticosteroids have generally positive results, long-term residual symptoms and associated activity limitations are common.
There is currently no standardised care for patients with ongoing activity limitation and participation restriction as a result of inflammatory neuropathy IN but data from observational studies and a randomised controlled trial suggest that exercise either alone or as part of a multidisciplinary rehabilitation programme may be beneficial in improving activity limitation. Tailoring the intervention for participants following physiotherapy assessment and incorporating patient preference for type and location of exercise may be important.

Methods/Design

The current study is a pragmatic, prospective, parallel observer-blind, randomised controlled trial to evaluate the efficacy and cost-effectiveness of a twelve week tailored home exercise programme versus advice and usual care. Seventy adults with stable immune mediated inflammatory neuropathy IN will be recruited to the study from two main sources: patients attending selected specialist peripheral nerve clinics in the South East and West Midlands of England and people with who access the GAIN charity website or newsletter. Participants will be randomised to receive either advice about exercise and usual care or a 12 week tailored home exercise programme.
The primary outcome of activity limitation and secondary outcomes of fatigue, quality of life, self-efficacy, illness beliefs, mood and physical activity will be assessed via self-report questionnaire at baseline, 12 weeks and 12 months post intervention. Cost effectiveness and cost utility will be assessed via interview at baseline and 12 months post intervention.
Intention to treat analysis will be our primary model for efficacy analysis. Semi-structured interviews will be conducted with a selected sample of participants in order to explore the acceptability of the intervention and factors affecting adherence to the exercise programme.

Discussion

This is the first randomised controlled trial to compare the efficacy and cost-effectiveness of tailored home exercise with advice about exercise and usual care for adults with inflammatory neuropathy.

Trial registration

Current Controlled Trials ISRCTN13311697
Literature
1.
Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in south-east England. Eur J Neurol. 2013;21:28–33.CrossRefPubMed
2.
Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245–57.CrossRefPubMed
3.
4.
Rubin DI. Acute and chronic polyradiculopathies. Continuum (MinneapMinn). 2011;17:831–54.
5.
6.
van den Berg B, Walgaatd C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82.CrossRefPubMed
7.
Lehmann HC, Hughes RAC, Hartung HP. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Handb Clin Neurol. 2013;115:415–27.CrossRefPubMed
8.
Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17:356–63.CrossRefPubMed
9.
Bernsen RA, de Jager AE, Kuijer W, van der Meche FG, Suurmeijer TP. Psychosocial dysfunction in the first year after Guillain-Barre syndrome. Muscle Nerve. 2002;41:533–9.CrossRef
10.
Bersano A, Carpo M, Allaria S, Franciotta D, Citterio A, Nobile-Orazio E. Long term disability and social status change after Guillain-Barre syndrome. J Neurol. 2006;253:214–8.CrossRefPubMed
11.
Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Widen HL. Impairment in Guillain-Barre syndrome during the first 2 years after onset: a prospective study. J Neurol Sci. 2004;227:131–8.CrossRefPubMed
12.
Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Holmqvist LW. Disability and health-related quality of life in Guillain-Barre syndrome during the first two years after onset: a prospective study. Clin Rehabil. 2005;19:900–9.CrossRefPubMed
13.
Westblad ME, Forsberg A, Press R. Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil. 2009;31:720–5.CrossRefPubMed
14.
Forsberg A, Press R, Holmqvist LW. Residual disability 10 years after falling ill in Guillain-Barre syndrome: a prospective follow-up study. J Neurol Sci. 2012;317:74–9.CrossRefPubMed
15.
Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999;53:1648–54.CrossRefPubMed
16.
Drory VE, Bronipolsky T, Bluvshtein V, Catz A, Korczyn AD. Occurrence of fatigue over 20 years after recovery from Guillain-Barre syndrome. J Neurol Sci. 2012;316:72–5.CrossRefPubMed
17.
Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. 2010;257:2024–31.CrossRefPubMed
18.
Royal E, Reynolds FA, Houlden H. What are the experiences of adults returning to work following recovery from Guillain-Barre syndrome? An interpretative phenomenological analysis. Disabil Rehabil. 2009;31:1817–27.CrossRefPubMed
19.
Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14:310–5.CrossRefPubMed
20.
Forsberg A, de Pedro-Cuesta J, Widen HL. Use of healthcare, patient satisfaction and burden of care in Guillain-Barre syndrome. J Rehabil Med. 2006;38:230–6.CrossRefPubMed
21.
McCrone P, Chisholm D, Knapp M, Hughes RAC, Comi G, Dalakas MC, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2003;10:687–94.CrossRefPubMed
22.
White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev. 2004;4:CD003904.PubMed
23.
Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies ISJ, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology. 2004;63:2393–5.CrossRefPubMed
24.
Graham RC, Hughes RA, White CM. A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. J Neurol. 2007;254:228–35.CrossRefPubMed
25.
Khan F, Pallant JF, Amatya B, Ng L, Gorelik A, Brand L. Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after Guillain-Barré syndrome: A randomized controlled trial. J Rehabil Med. 2011;43:638–46.CrossRefPubMed
26.
Bandura A. Social foundations of thought and action: A social cognitive theory. Englewood Cliffs (NK): Prentice Hall; 1986.
27.
Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviours. Prog Behav Modif. 1992;28:184–218.
28.
Adams J, White M. Are activity promotion interventions based on the transtheoretical model effective? A critical review. Br J Sports Med. 2003;37:106–14.CrossRefPubMedPubMedCentral
29.
Marcus BH, Simkin LR. The transtheoretical model: applications to exercise behavior. Med Sci Sports Exerc. 1994;26:1400–4.CrossRefPubMed
30.
Prochaska JO, Velicer WF. The transtheoretical model of health behaviour change. Am J Health Promot. 1997;12:38–48.CrossRefPubMed
31.
Marshall SJ, Biddle SJ. The transtheoretical model of behaviour change: a meta-analysis of applications to physical activity and exercise. Ann Behav Med. 2001;23:229–46.CrossRefPubMed
32.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(Suppl):S21–24.CrossRefPubMed
33.
Joint Task Force of the EFNS and the PNS. EFNS/PNS Guideline on management of CIDP-First Revision. J Peripher Nerv Syst. 2010;15(1):1–9. Erratum in J Peripher Nerv Syst. 2010;15(4):373.CrossRef
34.
Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77:973–6.CrossRefPubMedPubMedCentral
35.
Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Inflammatory Neuropathy Cause, Treatment (INCAT) group: Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002;72:596–601.CrossRefPubMedPubMedCentral
36.
Bull FC, the Expert Working Groups: Physical Activity Guidelines in the U.K.: Review and Recommendations. School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, 2010.
37.
Thomas S, Reading J, Shephard RJ. Revision of the Physical Activity Readiness Questionnaire (PAR-Q). Can J Sport Sci. 1992;17:338–45.PubMed
38.
Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs, 2nd Edition. London: Gaskell; 2001. p. 200–24.
39.
Dobkin BH. Rehabilitation after stroke, traumatic brain injury, and spinal cord injury: common denominators within recent clinical trials. Curr Opin Neurol. 2009;22:563–9.CrossRefPubMedPubMedCentral
40.
Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine (2011) Quantity and Quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43:1334–59.CrossRefPubMed
41.
Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16 Suppl 1:55–8.CrossRefPubMed
42.
Thein Brody L. Effective Therapeutic Exercise Prescription: The Right Exercise at the Right Dose. J Hand Ther. 2012;25:220–31.CrossRef
43.
44.
Kujala UM. Evidence on the effects of exercise therapy in the treatment of chronic disease. Br J Sports Med. 2009;43:550–5.CrossRefPubMed
45.
Harvey L, Glinsky J, Katalinic O, Messenger P, and the expert sub-committees: Website of physiotherapy exercises [www.​physiotherapyexe​rcises.​com] Final report 2007–2009 for New South Wales Department of Health, 2010.
46.
Wallace AC, Talelli P, Dileone M, Oliver R, Ward N, Cloud G, et al. Standardizing the intensity of upper limb treatment in rehabilitation medicine. Clin Rehabil. 2010;24:471–8.CrossRefPubMedPubMedCentral
47.
Jordan JL, Holden MA, Mason EE, Foster NE. Interventions to improve adherence to exercise for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2010;1:CD005956.PubMed
48.
van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76:337–45.CrossRefPubMed
49.
Draak THP, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology. 2014;83:2124–32.CrossRefPubMed
50.
van Nes SI, Vanhoutte EK, Faber CG, Garssen M, van Doorn PA, Merkies IS. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst. 2009;14:268–78.CrossRefPubMed
51.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
52.
Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36).1. Conceptual-Framework and Item Selection. Medical Care. 1992;30:473–83.CrossRefPubMed
53.
Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.CrossRefPubMed
54.
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381–95.CrossRefPubMed
55.
Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631–7.CrossRefPubMed
56.
Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The revised Illness Perception Questionnaire (IPQ-R). Psychol Health. 2002;17:1–16.CrossRef
57.
Resnick B, Jenkins LS. Testing the reliability and validity of the Self-Efficacy for Exercise scale. Nurs Res. 2000;49:154–9.CrossRefPubMed
58.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–7.CrossRefPubMed
59.
Curtis L: Unit costs of Health and Social Care 2013. PSSRU, University of Kent, Canterbury, 2013.
60.
61.
Cresswell JW, Plano Clark VL. Designing and conducting mixed methods research. 3. Thousand Oaks: Sage Publications; 2011.
Metadata
Title
Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy
Authors
Claire M. White
Robert D. Hadden
Sarah F. Robert-Lewis
Paul R. McCrone
Jane L. Petty
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-015-0398-x

Other articles of this Issue 1/2015

BMC Neurology 1/2015 Go to the issue

Case report

Diagnosing moyamoya syndrome using ultrasound - a case report

Study protocol

Caregiver-mediated exercises with e-health support for early supported discharge after stroke (CARE4STROKE): study protocol for a randomized controlled trial

Research article

Impact of sex in stroke thrombolysis: a coarsened exact matching study

Research article

Increased cortical activation upon painful stimulation in fibromyalgia syndrome

Case report

Progressive transcortical sensory aphasia and progressive ideational apraxia owing to temporoparietal cortical atrophy

Study protocol

Do cognitive measures and brain circuitry predict outcomes of exercise in Parkinson Disease: a randomized clinical trial